'The probability of this being a suckers' rally, where all kinds of beaten down stocks have begun to rally sharply, should be a time to be cautious and circumspect.'
The broader NSE Nifty rose 47.50 points, or 0.43 per cent, to 11,105.35. During the day, it climbed a peak of 11,141.75 and touched a low of 11,049.50.
"Zero is an unlikely figure. The virus is mutating and it is difficult to predict it's future behaviour,
'12250 should be considered a reasonable level to re-enter into the market.'
'To keep the next catastrophe at bay, a carbon free economy will be an imperative. 'Our 2000 cc internal combustion engine powered personal cars and public transport may have to give way to electric and hydrogen powered fuel cells. 'The oil refineries which were so much part of my professional life may have to be dismantled and trees planted in its place. 'The smokestacks, which once upon a time represented growth and prosperity, will now be gory symbols of a polluting past,' notes former Hindustan Petroleum chairman Arun Balakrishnan.
Tech sectors, including start-ups and IT & ITeS, witnessed the highest consolidation, capturing over 40 per cent of volumes
After a detailed scrutiny, fair trade watchdog CCI has suggested Sun Pharma and Ranbaxy to make certain changes in their proposed $4 billion merger deal, including possible divestment of some brands, to address anti-competitive concerns.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
The health system is trying to ensure that it isn't caught by surprise -- the way it was last time. So, hectic preparations are on.
As the virus ravaged rural areas, the state BJP figured out it was impossible to underplay or escape its impact on its political plans.
Sun Pharma expects synergy benefits by next fiscal.
'Is it advisable to have more number of scrips in small quantities or a few scrips in big quantities?'
Results of some blue-chip companies exceeded expectations, providing additional thrust, traders said.
'People are doing a lot of trading.' 'Short-term euphoria can be seen.' 'Retail participation is best through MFs and PMS.'
When Biocon chairperson Kiran Majumdar-Shaw - well known for raising issues ranging from lack of civic services in Bengaluru to climate change - decided to take on the Indian stock market regulator, the Securities and Exchange Board of India (Sebi), she forced the Indian corporate world and legal community to take notice. In an interview to Business Standard, Majumdar-Shaw called a Sebi order to impose a fine on insider trading charges against a Biocon employee and an external consultant an "Agatha Christie" fiction, which destroyed the reputation of "innocent people". "The order is pure harassment and has caused huge reputational damage to us and goes against the principles of good governance promised by this government," Mazumdar-Shaw said. "We will certainly appeal this," she added.
Market players said a big upmove by the market will depend on policy action by the government to revive economic growth and corporate earnings revival.
'What really works is the core story, the characters who come together, the twists and turns, and, above all, Sushmita Sen,' notes Joginder Tuteja.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The phased reopening and regulated relaxations of many key industries have paved the way for a slight recovery in hiring activities but hiring is still down by 47 per cent in July 2020 compared to the same month last year.
Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.
Finance Minister Nirmala Sitharaman on Monday assured the industry that momentum of economic reforms will continue to make India a hotspot of global investment. India has turned the crisis created by COVID-19 pandemic into an opportunity to push the economic reforms, which remained pending for decades, she said while addressing the National MNC's Conference 2020 organised by industry chamber CII.
50-odd biz leaders are part of Modi's entourage for the 3-nation tour
Despite the failure of most e-commerce players to meet orders through the first week of the lockdown, there has been no serious crisis, thanks to supplies from 11 million small kirana and mom-and-pop stores across the country with the support of over 300,000 distributors and wholesalers.
The Halol facility is important for the company as it accounts for 10 per cent of Sun Pharma's sales.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
Three stockmarket experts give their best picks for the New Year.
'Investors should plan and make investments strictly on the basis of their risk profile.' 'They should not bite more than they can chew.'
Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.
Engineering graduates specialising in artificial intelligence and machine learning can earn up to 24 lakh a year, says Saran Balasundaram, founder and CEO, HanDigital, a talent consulting firm.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
Prime Minister Narendra Modi on Saturday hard sold his government's reforms spanning from manufacturing to taxation to labour, saying they have changed the world perception about the country from 'why India' to 'why not India' and went on to quote record foreign investment during the pandemic as a testimony to that. Speaking at industry association Assocham's Foundation Week event, Modi also said agriculture reforms brought by his government six months back have started benefiting farmers. The reforms in the last six years have influenced in changing the sentiment of the industry from 'why India' to 'why not India' in investing.
India Inc is ready to diversify into unchartered areas.
There are 20,000 pharma companies in India scrambling to get doctors to prescribe their drugs.
'What has gained prominence are 'human' skills like creativity, originality and initiative, critical thinking, persuasion, and negotiation, as well as attention to detail, resilience, flexibility and complex problem-solving.'
Market cap of government companies has remained unchanged in the past 8 years.
The haircut for major banks stands at 52 per cent, if the dues of Jaypee Infrastructure, Lanco Infrastructure and Era Infrastructure are kept out of the calculation.
Data also show that several other leading domestic pharma companies have recalled their products from the US
'Younger people are taking steps to prevent lifestyle diseases.'
'It is fascinating to partner with consumers on the journey of self-discovery and to help shape people's preferences -- that is what I find most exciting,' Nandini Piramal tells Abhineet Kumar and Aneesh Phadnis.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances